In the Journals

This feature offers timely executive summaries of the most relevant journals in rheumatology. Through peer “Perspectives,” full bibliographical information and links to the original journal abstract, In the Journals are a step wider and deeper than journal reviews health care professionals may be accustomed.

In the Journals

Patients with low-disease RA on tofacitinib, methotrexate can safely withdraw methotrexate

September 12, 2019
Patients with rheumatoid arthritis who achieve low disease activity with tofacitinib plus methotrexate can safely withdraw methotrexate without fear…
In the Journals

Stress ‘primary driver’ for fatigue in patients with SLE

September 12, 2019
Although depression and stress are both predictors of fatigue among patients with systemic lupus erythematosus at 1 year, stress is the…
In the Journals

Quarter of axial SpA patients attain inactive disease after 6 months on first TNF inhibitor

September 11, 2019
Among patients with axial spondyloarthritis receiving their first TNF inhibitor, 27% achieve inactive disease, defined by the Ankylosing Spondylitis…
In the Journals

Patient-reported symptoms linked to disease activity changes in SSc

September 10, 2019
Patient-reported symptoms are associated with clinically impactful changes in systemic sclerosis disease activity, according to findings published in…
In the Journals

Number of prior DMARDs, disease duration linked to diminished drug response in RA

September 9, 2019
Longer disease duration and a greater number of previous DMARDs in a patient’s history is associated with decreased response rates to…
In the JournalsPerspective

Patients with gout have 30% higher risk for chronic kidney disease

September 9, 2019
Gout is associated with a 29% increased risk for developing advanced chronic kidney disease and a 210% increased risk for end-stage renal disease…
In the JournalsPerspective

Telemedicine more commonly used by patients with higher RA activity

September 5, 2019
Video telemedicine, when it is offered, is more likely to be used by patients with rheumatoid arthritis who demonstrate higher disease activity, have…
In the JournalsPerspective

Adalimumab well-tolerated by most children with polyarticular JIA

September 5, 2019
Adalimumab, with or without methotrexate, is well-tolerated over a period of at least 7 years among most children with polyarticular-course juvenile…
In the Journals

Golimumab efficacy in RA similar for patients older, younger than 65 years

September 4, 2019
IV golimumab, combined with methotrexate, is as efficacious among patients with rheumatoid arthritis who are aged 65 years and older as it is among…
In the JournalsPerspective

Immune-related adverse effects of checkpoint inhibitors frequent but manageable

September 4, 2019
Although flares and immune-related adverse effects due to checkpoint inhibitor therapy can be frequent and potentially severe, they are “mostly…